Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

Por Chène, Patrick, Rudloff, Joëlle, Schoepfer, Joseph, Furet, Pascal, Meier, Peter, Qian, Zhiyan, Schlaeppi, Jean-Marc, Schmitz, Rita, Radimerski, Thomas
Publicado em 2009

Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes

Por Kallen, Joerg, Goepfert, Arnaud, Blechschmidt, Anke, Izaac, Aude, Geiser, Martin, Tavares, Gisele, Ramage, Paul, Furet, Pascal, Masuya, Keiichi, Lisztwan, Joanna
Publicado em 2009

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

Por Martiny-Baron, Georg, Holzer, Philipp, Billy, Eric, Schnell, Christian, Brueggen, Joseph, Ferretti, Mireille, Schmiedeberg, Niko, Wood, Jeanette M., Furet, Pascal, Imbach, Patricia
Publicado em 2010

2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4

Por Knoepfel, Thomas, Furet, Pascal, Mah, Robert, Buschmann, Nicole, Leblanc, Catherine, Ripoche, Sebastien, Graus-Porta, Diana, Wartmann, Markus, Galuba, Inga, Fairhurst, Robin A.
Publicado no ACS Med Chem Lett (2018)

Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface

Por Mesrouze, Yannick, Bokhovchuk, Fedir, Izaac, Aude, Meyerhofer, Marco, Zimmermann, Catherine, Fontana, Patrizia, Schmelzle, Tobias, Erdmann, Dirk, Furet, Pascal, Kallen, Joerg, Chène, Patrick
Publicado no Protein Sci (2018)

Correction to “2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4”

Por Knoepfel, Thomas, Furet, Pascal, Mah, Robert, Buschmann, Nicole, Leblanc, Catherine, Ripoche, Sebastien, Graus-Porta, Diana, Wartmann, Markus, Galuba, Inga, Fairhurst, Robin A.
Publicado no ACS Med Chem Lett (2020)

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Por Cowan-Jacob, Sandra W., Fendrich, Gabriele, Floersheimer, Andreas, Furet, Pascal, Liebetanz, Janis, Rummel, Gabriele, Rheinberger, Paul, Centeleghe, Mario, Fabbro, Doriano, Manley, Paul W.
Publicado em 2006

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison

Por Weisberg, Ellen, Roesel, Johannes, Furet, Pascal, Bold, Guido, Imbach, Patricia, Flörsheimer, Andreas, Caravatti, Georgio, Jiang, Jingrui, Manley, Paul, Ray, Arghya, Griffin, James D.
Publicado em 2010

Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors

Por Bokhovchuk, Fedir, Mesrouze, Yannick, Delaunay, Clara, Martin, Typhaine, Villard, Frédéric, Meyerhofer, Marco, Fontana, Patrizia, Zimmermann, Catherine, Erdmann, Dirk, Furet, Pascal, Scheufler, Clemens, Schmelzle, Tobias, Chène, Patrick
Publicado no Protein Sci (2019)

p53 dynamics vary between tissues and are linked with radiation sensitivity

Por Stewart-Ornstein, Jacob, Iwamoto, Yoshiko, Miller, Miles A., Prytyskach, Mark A., Ferretti, Stephane, Holzer, Philipp, Kallen, Joerg, Furet, Pascal, Jambhekar, Ashwini, Forrester, William C., Weissleder, Ralph, Lahav, Galit
Publicado no Nat Commun (2021)

Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).

Por Sarno, Stefania, de Moliner, Erika, Ruzzene, Maria, Pagano, Mario A, Battistutta, Roberto, Bain, Jenny, Fabbro, Doriano, Schoepfer, Joseph, Elliott, Matthew, Furet, Pascal, Meggio, Flavio, Zanotti, Giuseppe, Pinna, Lorenzo A
Publicado em 2003

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region

Por Fairhurst, Robin A., Knoepfel, Thomas, Leblanc, Catherine, Buschmann, Nicole, Gaul, Christoph, Blank, Jutta, Galuba, Inga, Trappe, Jörg, Zou, Chao, Voshol, Johannes, Genick, Christine, Brunet-Lefeuvre, Peggy, Bitsch, Francis, Graus-Porta, Diana, Furet, Pascal
Publicado no Medchemcomm (2017)

A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors

Por Mesrouze, Yannick, Aguilar, Gustavo, Bokhovchuk, Fedir, Martin, Typhaine, Delaunay, Clara, Villard, Frédéric, Meyerhofer, Marco, Zimmermann, Catherine, Fontana, Patrizia, Wille, Roman, Vorherr, Thomas, Erdmann, Dirk, Furet, Pascal, Scheufler, Clemens, Schmelzle, Tobias, Affolter, Markus, Chène, Patrick
Publicado no Sci Rep (2020)

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors

Por Hoegenauer, Klemens, Soldermann, Nicolas, Stauffer, Frédéric, Furet, Pascal, Graveleau, Nadege, Smith, Alexander B., Hebach, Christina, Hollingworth, Gregory J., Lewis, Ian, Gutmann, Sascha, Rummel, Gabriele, Knapp, Mark, Wolf, Romain M., Blanz, Joachim, Feifel, Roland, Burkhart, Christoph, Zécri, Frédéric
Publicado no ACS Med Chem Lett (2016)

Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo

Por Honda, Ayako, Harrington, Edmund, Cornella-Taracido, Ivan, Furet, Pascal, Knapp, Mark S., Glick, Meir, Triantafellow, Ellen, Dowdle, William E., Wiedershain, Dmitri, Maniara, Wieslawa, Moore, Christine, Finan, Peter M., Hamann, Lawrence G., Firestone, Brant, Murphy, Leon O., Keaney, Erin P.
Publicado no ACS Med Chem Lett (2015)

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

Por Weisberg, Ellen, Roesel, Johannes, Bold, Guido, Furet, Pascal, Jiang, Jingrui, Cools, Jan, Wright, Renee D., Nelson, Erik, Barrett, Rosemary, Ray, Arghya, Moreno, Daisy, Hall-Meyers, Elizabeth, Stone, Richard, Galinsky, Ilene, Fox, Edward, Gilliland, Gary, Daley, John F., Lazo-Kallanian, Suzan, Kung, Andrew L., Griffin, James D.
Publicado em 2008

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Por Jeay, Sébastien, Gaulis, Swann, Ferretti, Stéphane, Bitter, Hans, Ito, Moriko, Valat, Thérèse, Murakami, Masato, Ruetz, Stephan, Guthy, Daniel A, Rynn, Caroline, Jensen, Michael R, Wiesmann, Marion, Kallen, Joerg, Furet, Pascal, Gessier, François, Holzer, Philipp, Masuya, Keiichi, Würthner, Jens, Halilovic, Ensar, Hofmann, Francesco, Sellers, William R, Graus Porta, Diana
Publicado no eLife (2015)

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097

Por Jeay, Sébastien, Gaulis, Swann, Ferretti, Stéphane, Bitter, Hans, Ito, Moriko, Valat, Thérèse, Murakami, Masato, Ruetz, Stephan, Guthy, Daniel A, Rynn, Caroline, Jensen, Michael R, Wiesmann, Marion, Kallen, Joerg, Furet, Pascal, Gessier, François, Holzer, Philipp, Masuya, Keiichi, Würthner, Jens, Halilovic, Ensar, Hofmann, Francesco, Sellers, William R, Graus Porta, Diana
Publicado no eLife (2016)

Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma

Por Goyal, Lipika, Saha, Supriya K., Liu, Leah Y., Siravegna, Giulia, Leshchiner, Ignaty, Ahronian, Leanne G., Lennerz, Jochen K., Vu, Phuong, Deshpande, Vikram, Kambadakone, Avinash, Mussolin, Benedetta, Reyes, Stephanie, Henderson, Laura, Sun, Jiaoyuan Elisabeth, Van Seventer, Emily E., Gurski, Joseph M., Baltschukat, Sabrina, Schacher-Engstler, Barbara, Barys, Louise, Stamm, Christelle, Furet, Pascal, Ryan, David P., Stone, James R., Iafrate, A. John, Getz, Gad, Porta, Diana Graus, Tiedt, Ralph, Bardelli, Alberto, Juric, Dejan, Corcoran, Ryan B., Bardeesy, Nabeel, Zhu, Andrew X.
Publicado no Cancer Discov (2016)